Overview
Portfolio
More
Szgig
Supports the growth of global healthcare enterprises through theme‑based investments across the healthcare sector.
Portfolio
49+
Employees
<3
Founded
N/A
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
China
Sources
Showing 13 of 13 matched portfolio companies
3hPharma provides a cloud‑based platform that centralizes drug discovery and development data across laboratory, pre‑clinical, and clinical stages. The system offers real‑time analytics, automated compliance tools for FDA 21 CFR Part 11, and secure, role‑based collaboration workspaces, enabling pharma R&D teams and CROs to manage data, streamline documentation, and accelerate decision‑making without heavy IT overhead.
AbB Biotech specializes in the research and development of multivalent vaccines that target multiple pathogens simultaneously, enhancing immune response and protection. The company addresses the need for more effective vaccination strategies to combat emerging infectious diseases and improve public health outcomes.
Atom Bioscience is a clinical-stage biotechnology company focused on developing targeted therapies for rare genetic disorders using gene editing technologies. Their approach aims to provide precise treatment options that address the underlying genetic causes of these conditions, improving patient outcomes and quality of life.
BridGene Biosciences utilizes its proprietary IMTAC™ platform, which combines covalent chemistry and quantitative mass spectrometry, to screen small molecules against the entire proteome in live cells. This approach targets approximately 90% of disease-associated proteins that lack known binding sites, enabling the discovery of therapeutic candidates for previously undruggable targets.
Chamlion provides end-to-end digital dentistry solutions utilizing metal 3D printing technology to produce dental crowns, frameworks, and removable partial dentures with high precision and efficiency. The company addresses the need for faster production times and improved quality in dental prosthetics by integrating a comprehensive digital platform that streamlines the entire manufacturing process.
Elpiscience is a clinical-stage biopharmaceutical company developing next-generation cancer immunotherapies using proprietary monoclonal and bispecific antibody technologies. The company aims to improve treatment outcomes for cancer patients by advancing targeted therapies that engage the immune system to eliminate tumors.
The startup develops targeted therapies for cancer treatment through drug discovery focused on tumor immunology. By enhancing the immune response against tumors, the company aims to improve the quality of life for cancer patients.
Funding: $20.0M
Rough estimate of the amount of funding raised
Funding: $20.0M
Rough estimate of the amount of funding raised
Hotgen provides a multi‑omics diagnostic platform that combines magnetic‑particle chemiluminescence, exosome capture, and DNA‑methylation assays to deliver high‑sensitivity biomarker measurements from a single sample. The company also offers handheld, automated analyzers for point‑of‑care testing and leverages the same technology to develop antibody and nucleic‑acid therapeutics, such as the SGC001 myocardial‑infarction antibody.
Luo provides a platform for African businesses to convert XOF into USD or EUR and execute international payments within 48 hours, ensuring zero transaction fees and competitive exchange rates. This service addresses the challenge of slow and costly cross-border payments, enabling efficient supplier transactions for businesses in Senegal and Côte d'Ivoire.
Lyvgen Biopharma develops cross-linking dependent monoclonal antibodies and next-generation multi-antibody platforms to enhance tumor immunotherapy by activating immune responses against cancer cells. Their technology specifically targets the tumor microenvironment, improving the precision and safety of treatments while promoting the proliferation and function of anti-tumor immune cells.
TenNor Therapeutics focuses on the research and development of novel pharmacological agents targeting digestive diseases, utilizing advanced drug discovery techniques and preclinical models. The company aims to improve treatment outcomes for patients suffering from conditions such as inflammatory bowel disease and gastrointestinal disorders.
5+
100+Approximate amount of employees
Funding: $42.1M
Rough estimate of the amount of funding raised
Funding: $42.1M
Rough estimate of the amount of funding raised
United Imaging builds ultra‑high‑field MRI, high‑definition PET/MR, and total‑body PET‑CT systems that deliver whole‑body imaging with superior resolution, faster scans, and low radiation dose. Their integrated hardware and AI‑assisted software enable clinicians to capture anatomical, functional, and molecular data in a single exam, supporting earlier diagnosis and precise treatment planning for large hospitals and research centers.
Showing 12 of 36 unmatched portfolio companies